C-Path and Replica Analytics Collaboration Aims to Accelerate Rare Disease Research NEW YORK, OTTAWA and TUCSON, Ariz., June 29, 2022 — Critical Path Institute (C-Path) and Replica Analytics, an Aetion company, a
C-Path Welcomes RWS C-Path is proud to welcome RWS as the newest member of its Electronic Clinical Outcome Assessment (eCOA) Consortium. Compri
C-Path Welcomes Parexel C-Path is proud to welcome Parexel as the newest member of its Electronic Clinical Outcome Assessment (eCOA) Consortium. Compri
eCOA Consortium Announces Next Article in a Series for Applied Clinical Trials C-Path’s eCOA Consortium is pleased to announce that “Progressing BYOD Adoption” has been published in Applied Clinical Tria
C-Path Receives DIA 2022 Americas Inspire Award for Outstanding Contribution to Health TUCSON, Ariz., June 22, 2022 — Critical Path Institute (C-Path) is pleased to announce it has received the DIA 2022 Ameri
C-Path Launches Unique Translational Therapeutics Accelerator with Support from Cottrell Foundation The global accelerator will transform academic discoveries to drug development opportunities TUCSON, Ariz., June 9, 2022 — Criti
June 8, 2022 Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ): measurement properties and estimated clinically meaningful thresholds from a phase 3 study
June 8, 2022 PRO Consortium Announces Publication of Open Access Article C-Path’s PRO Consortium is pleased to announce that “Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ)